You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Peer Insights: Sequencing Therapies for Patients With BRAF-Mutant Metastatic Melanoma

  • Authors: Michael B. Atkins, MD
  • CME / ABIM MOC / CE Released: 11/14/2022
  • Valid for credit through: 11/14/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    Nurses - 0.50 ANCC Contact Hour(s) (0.5 contact hours are in the area of pharmacology)

    Pharmacists - 0.50 Knowledge-based ACPE (0.050 CEUs)

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for oncologists, dermatologists, surgeons, pathologists, nurses, nurse practitioners, pharmacists, and other members of the interprofessional team.

The goal of this activity is that learners will be better able to identify current and emerging data on sequencing therapies in BRAF-mutant metastatic melanoma and individualize care for patients.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical trial data evaluating sequencing therapies for the management of patients with BRAF-mutant metastatic melanoma
  • Demonstrate improved competence associated with
    • Creating customized care plans for patients with BRAF-mutant metastatic melanoma
    • Managing potential adverse events associated with therapies used to treat BRAF-mutant metastatic melanoma
  • Demonstrate greater confidence in their ability to
    • Optimize care for patients with BRAF-mutant metastatic melanoma


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Michael B. Atkins, MD

    Deputy Director
    Georgetown Lombardi Comprehensive Cancer Center
    William M. Scholl Professor and Vice Chair
    Department of Oncology
    Georgetown University Medical Center
    Washington, DC

    Disclosures

    Michael B. Atkins, MD, has the following relevant financial relationships:
    Consultant or advisor for: Agenus; Asher Bio; AstraZeneca; AVEO; Bristol Myers Squibb; Calithera; COTA; Eisai; Elpis; Exelixis; Fathom; Idera; Iovance Biotherapeutics; Merck; Novartis Pharmaceuticals; PACT; Pfizer; Pyxis Oncology; Roche; SAB Bio; Sanofi; ScholarRock; Seagen Inc.; Simcha; Surface Oncology; Takeda; ValoHealth; Werewolf; X4Pharma
    Research funding from: Bristol Myers Squibb; Genentech-Roche; Merck
    Owns stock (publicly traded) in: Pyxis Oncology; Werewolf

Editor

  • Deborah Middleton, MS

    Senior Medical Education Director, WebMD Global, LLC 

    Disclosures

    Deborah Middleton, MS, has no relevant financial relationships.  

Compliance Reviewer/Nurse Planner

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 0.50 contact hour(s) ( 0.050 CEUs) (Universal Activity Number: JA0007105-0000-22-243-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Peer Insights: Sequencing Therapies for Patients With BRAF-Mutant Metastatic Melanoma

Authors: Michael B. Atkins, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 11/14/2022

Valid for credit through: 11/14/2023

processing....

Learning Feedback Questions

Please answer these questions to complement your learning experience.